 - Derived benefit from PD 0332991 in the neoadjuvant setting in this trial. This includes the 26 patients who achieved complete cell cycle arrest only after the addition of PD 0332991 C1D1 Ki67 2.7 and C1D15 Ki67 2.7 from the main study PIK3CA WT, mutant, or unknown cohorts as well as any patients who have a Ki67 10 on C1D15 biopsy in the endocrine resistant cohort 